<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>A Systemic Pathological Network Model and Combinatorial Intervention Strategies for Alzheimer's Disease - Health AI Hub</title>
    <meta name="description" content="This paper proposes a systemic pathological network model for Alzheimer's disease (AD), integrating amyloid-$Œ≤$, tau, and neuroinflammation as intricately inter">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>A Systemic Pathological Network Model and Combinatorial Intervention Strategies for Alzheimer's Disease</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.04937v1" target="_blank">2512.04937v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-04
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> She Xutong
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.MN
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.04937v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.04937v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper proposes a systemic pathological network model for Alzheimer's disease (AD), integrating amyloid-$Œ≤$, tau, and neuroinflammation as intricately interacting pathologies, moving beyond the linear amyloid cascade hypothesis. It advocates for a paradigm shift in AD management towards preemptive, biomarker-guided, and personalized combination interventions that simultaneously target these multiple pathways, leveraging early diagnostic detection and emerging technological platforms.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This paper provides a critical framework for understanding AD as a multi-faceted disease, directly addressing the urgent need for more effective treatments by proposing a shift from single-target therapies to comprehensive, personalized combination interventions, thereby accelerating the path towards impactful clinical strategies.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper explicitly highlights 'AI-driven patient stratification' as a future component in managing Alzheimer's disease, aiming for preemptive, biomarker-guided, and personalized combination interventions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>AD pathogenesis is reconceptualized as a 'phase-adapted pathological network model' involving complex cross-talk between A$Œ≤$, tau, and neuroinflammation, rather than a singular linear cascade.</li>
                    
                    <li>Diagnostic paradigms have advanced to biomarker-based strategies, such as the AT(N) framework, enabling early disease detection during preclinical or prodromal AD stages.</li>
                    
                    <li>Anti-A$Œ≤$ monoclonal antibodies (e.g., lecanemab, donanemab) represent a breakthrough as disease-modifying therapies, but their modest efficacy underscores the limitations of single-target approaches.</li>
                    
                    <li>The paper provides a compelling rationale for combination therapies that simultaneously target A$Œ≤$ pathology, aberrant tau, and neuroinflammation to overcome the limitations of current single-target interventions.</li>
                    
                    <li>Emerging technological platforms, including gene editing and biophysical neuromodulation, are highlighted as crucial for advancing precision medicine in AD.</li>
                    
                    <li>A future roadmap for AD management involves the integration of early biomarker detection, multi-target therapeutic strategies, and AI-driven patient stratification.</li>
                    
                    <li>The ultimate vision is for AD management to be defined by preemptive, biomarker-guided, and personalized combination interventions, fundamentally altering the disease trajectory.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>This paper is a review and synthesis of existing scientific understanding, proposing a conceptual 'systemic pathological network model' for AD and outlining combinatorial intervention strategies. It analyzes the current pathophysiological understanding, diagnostic paradigms, and therapeutic landscape to build a rationale for future directions; it does not present new experimental data.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The key findings include the inadequacy of the linear amyloid cascade hypothesis, leading to the proposal of a comprehensive 'pathological network model' for AD. It identifies the modest efficacy of single-target anti-A$Œ≤$ therapies as a critical limitation, thereby advocating for multi-target combination therapies addressing A$Œ≤$, tau, and neuroinflammation. Furthermore, it highlights the essential role of early biomarker-based diagnostics and emerging technologies like gene editing and biophysical neuromodulation for future precision medicine in AD.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This analysis will significantly impact clinical practice by advocating for a shift towards multi-drug regimens for AD, mirroring approaches in other complex diseases. It underscores the importance of widespread early biomarker screening for timely intervention and will guide the development of personalized treatment plans. It also encourages research into novel therapeutic targets beyond A$Œ≤$ and tau, especially those related to neuroinflammation, and the integration of advanced technologies into clinical care.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The paper explicitly notes the 'modest efficacy' of current single-target anti-A$Œ≤$ monoclonal antibodies as a major limitation in AD therapeutics. Implicitly, the complexity of the proposed 'pathological network' and the development of effective multi-target combination therapies represent significant ongoing challenges that are not yet fully overcome.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Future directions include the research, development, and clinical implementation of multi-target combination therapies simultaneously addressing A$Œ≤$, tau, and neuroinflammation. It emphasizes further integration and refinement of early biomarker detection strategies for patient stratification and therapeutic guidance. Additionally, it highlights the exploration and application of emerging technologies such as gene editing, biophysical neuromodulation, and AI-driven patient stratification for precision AD management, moving towards preemptive and personalized interventions.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Neurology</span>
                    
                    <span class="tag">Neuropharmacology</span>
                    
                    <span class="tag">Diagnostics</span>
                    
                    <span class="tag">Biomarkers</span>
                    
                    <span class="tag">Geriatric Medicine</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                    <span class="tag">Neuroimmunology</span>
                    
                    <span class="tag">Genetic Engineering</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Alzheimer's disease</span>
                    
                    <span class="tag tag-keyword">amyloid-$Œ≤$</span>
                    
                    <span class="tag tag-keyword">tau pathology</span>
                    
                    <span class="tag tag-keyword">neuroinflammation</span>
                    
                    <span class="tag tag-keyword">combination therapy</span>
                    
                    <span class="tag tag-keyword">multi-target therapy</span>
                    
                    <span class="tag tag-keyword">precision medicine</span>
                    
                    <span class="tag tag-keyword">biomarkers</span>
                    
                    <span class="tag tag-keyword">gene editing</span>
                    
                    <span class="tag tag-keyword">neuromodulation</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Alzheimer's disease (AD) persists as a paramount challenge in neurological research, characterized by the pathological hallmarks of amyloid-$Œ≤$ (A$Œ≤$) plaques and neurofibrillary tangles composed of hyperphosphorylated tau. This review synthesizes the evolving understanding of AD pathogenesis, moving beyond the linear amyloid cascade hypothesis to conceptualize the disease as a cross-talk of intricately interacting pathologies, encompassing A$Œ≤$, tau, and neuroinflammation as the foundation of phase-adapted pathological network model. This evolving pathophysiological understanding parallels a transformation in diagnostic paradigms, where biomarker-based strategies such as the AT(N) framework enable early disease detection during preclinical or prodromal stages. Within this new landscape, while anti-A$Œ≤$ monoclonal antibodies (e.g., lecanemab, donanemab), represent a breakthrough as the first disease-modifying therapies, their modest efficacy underscores the limitation of single-target approaches. Therefore, I explore the compelling rationale for combination therapies that simultaneously target A$Œ≤$ pathology, aberrant tau, and neuroinflammation. Looking forward, I emphasize emerging technological platforms such as gene editing and biophysical neuromodulation in advancing precision medicine. Ultimately, the integration of early biomarker detection, multi-target therapeutic strategies, and AI-driven patient stratification charts a promising roadmap toward fundamentally altering the trajectory of AD. The future of AD management will be defined by preemptive, biomarker-guided, and personalized combination interventions.
Keywords: Alzheimer's disease, amyloid-$Œ≤$, tau pathology, neuroinflammation, combination therapy, multi-target therapy, precision medicine, biomarkers</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>23 pages</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>